PROVENTION BIO, INC.

PRVB NASDAQ
11.36
-0.36
-3.07%
盘后: 11.44 +0.08 +0.70% 18:27 06/17 EDT
开盘
11.90
昨收
11.72
最高
12.75
最低
11.36
成交量
158.61万
成交均量(3M)
72.00万
52周最高
22.82
52周最低
1.520
换手率
4.25%
市值
4.24亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供PROVENTION BIO, INC. PRVB股票价格,PROVENTION BIO, INC.股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.
展开 >

最近浏览

名称
价格
涨跌幅